BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages

In this prospective observational cohort study we analyzed cellular and serological immune response parameters against SARS-CoV-2 and current variants of concern (VOC) in 147 COVID-19-convalescent and 39 COVID-19-naïve individuals before and after BNT162b2 booster vaccination. No significant differe...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Frontiers in Immunology
المؤلفون الرئيسيون: Bernd Jahrsdörfer, Matthias Proffen, Judith Scholz, Janina Hägele, Carolin Ludwig, Christiane Vieweg, Aline Grempels, Dorit Fabricius, Ramin Lotfi, Sixten Körper, Guido Adler, Hubert Schrezenmeier
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Frontiers Media S.A. 2022-06-01
الموضوعات:
COVID-19
mRNA vaccine
BNT162b2
neutralization capacity
B.1.1.529
omicron
الوصول للمادة أونلاين:https://www.frontiersin.org/articles/10.3389/fimmu.2022.920210/full

الانترنت

https://www.frontiersin.org/articles/10.3389/fimmu.2022.920210/full

مواد مشابهة